Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L StudyHirotsugu Kenmotsu, Toshiaki Takahashi, Shunichi Sugawara et al.|Journal of Thoracic Oncology|2022Cited by 158
Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-AnalysisShiting Xu, Kazuhisa Takahashi, Takehito Shukuya et al.|JTO Clinical and Research Reports|2022Cited by 36